Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Artrya Limited ( (AU:AYA) ).
Artrya Limited has signed a five-year contract valued at US$0.6 million with Tanner Health, marking its first revenue in the U.S. market with the commercial launch of its Salix® Coronary Anatomy platform. This agreement is a significant milestone for Artrya as it transitions to a revenue-generating phase and integrates its platform across Tanner Health’s network, providing a pathway for future revenue opportunities with additional modules pending FDA clearance. The collaboration with Tanner Health not only validates the clinical utility of Artrya’s technology but also sets a precedent for future U.S. rollouts, enhancing its industry positioning and expanding its market presence.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.21 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company that specializes in AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. Artrya is focused on advancing cardiac care through innovative technology and is actively engaged in regulatory and commercial activities across key international markets.
Average Trading Volume: 192,070
Technical Sentiment Signal: Buy
See more insights into AYA stock on TipRanks’ Stock Analysis page.